Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Co., Ltd. is restarting its IPO process to list on the Hong Kong Stock Exchange after previously unsuccessful attempts to go public in the A-share market, indicating a strategic shift in its funding approach [1][3]. Company Overview - Xinhehua has been in the traditional Chinese medicine sector for 24 years, focusing on the production of traditional Chinese medicine pieces, with products distributed nationwide [3]. - The company ranks second in the Chinese market for traditional Chinese medicine pieces, holding a market share of 0.4% as of 2024, with the top five market participants collectively holding 2.7% [3]. Financial Performance - Revenue figures for Xinhehua are as follows: - 2022: RMB 780 million - 2023: RMB 1.145 billion - 2024: RMB 1.249 billion [4] - Gross profit for the same years was: - 2022: RMB 165 million (21.1% gross margin) - 2023: RMB 212 million (18.5% gross margin) - 2024: RMB 213 million (17.1% gross margin) [4] - Net profit peaked in 2023 at RMB 104 million but is projected to decline to RMB 89 million in 2024, with net profit margins decreasing from 9.9% in 2022 to 7.1% in 2024 [4][5]. Recent Developments - In the first half of 2025, Xinhehua reported revenue of RMB 633 million and a profit of RMB 51 million, reflecting a 17% year-on-year increase in profit [5]. - The company produces 10 types of toxic traditional Chinese medicine pieces and offers approximately 760 types of ordinary traditional Chinese medicine pieces, with ordinary pieces accounting for 89.6% of revenue [5]. Shareholding Structure - Prior to the IPO, the shareholding structure is highly concentrated, with founder Jiang Yun's family controlling 65.29% of the shares [6]. - Jiang Yun directly holds 31.54% and through Guojia Investment holds an additional 15.60% [6]. Cash Flow and Dividend Concerns - Xinhehua has faced deteriorating operating cash flow, with a net outflow of RMB 46,700 in 2024, contrasting with previous inflows [6]. - The company declared dividends of RMB 14.51 million in 2022 and executed a significant capital reduction of RMB 93.74 million in 2024, raising questions about the rationale behind these financial decisions amid cash flow challenges [6][7].

Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Co., Ltd. (referred to as "Xinhehua") has submitted an application for an IPO on the Hong Kong Stock Exchange, with Guangfa Securities (Hong Kong) and Agricultural Bank of China International as sponsors. The company aims to raise funds to expand its production capacity and explore overseas markets [1][10]. Group 1: Company Overview - Xinhehua specializes in the research, production, and sales of traditional Chinese medicine pieces, ranking second in China based on revenue from traditional Chinese medicine products in 2023 [2][3]. - The company has attempted to list on the A-share market multiple times but has not succeeded [2][10]. Group 2: Financial Performance - Xinhehua's revenue for the years 2022, 2023, and 2024 was 780.4 million RMB, 1.146 billion RMB, and 1.249 billion RMB, respectively, with net profits of 77.4 million RMB, 104.6 million RMB, and 89.1 million RMB [3][4]. - The gross profit margin has been declining, with total gross margins of 21.1%, 18.5%, and 17.1% for the years 2022, 2023, and 2024 [5][6]. Group 3: Product and Market Dynamics - A significant portion of Xinhehua's revenue comes from a limited range of products, with the top five products accounting for 26.5% of total annual revenue in 2024 [5]. - The gross profit margin for toxic traditional Chinese medicine pieces decreased from 29.7% in 2022 to 19.1% in 2024, while the margin for ordinary pieces fell from 19.6% to 16.7% during the same period [5][6]. Group 4: Future Plans and Use of Proceeds - The funds raised from the IPO will be used for expanding production capacity, upgrading digital production systems, enhancing sales and marketing activities, establishing overseas sales channels in Vietnam and Malaysia, and strategic investments and potential acquisitions [10].

Core Viewpoint - Xin He Hua is one of the leading and largest suppliers of traditional Chinese medicine (TCM) decoction pieces in China, ranking second in revenue for TCM decoction pieces in 2023 and is the fastest-growing among the top five market participants, with a compound annual growth rate (CAGR) of 27% from 2022 to 2024 [2]. Revenue Summary - The company's revenue for the years 2022, 2023, and 2024 is projected to be 780.417 million RMB, 1,145.571 million RMB, and 1,249.402 million RMB respectively [3][6]. - The revenue breakdown shows that toxic decoction pieces contributed 115.302 million RMB (14.8%) in 2022, 192.492 million RMB (16.8%) in 2023, and is expected to be 172.433 million RMB (13.8%) in 2024. Ordinary decoction pieces accounted for 665.115 million RMB (85.2%) in 2022, 953.079 million RMB (83.2%) in 2023, and is projected to be 1,076.969 million RMB (86.2%) in 2024 [3]. Gross Profit Summary - Gross profit for the years 2022, 2023, and 2024 is reported as 164.641 million RMB, 212.018 million RMB, and 213.073 million RMB respectively, with corresponding gross profit margins of 21.1%, 18.5%, and 17.1% [4][5]. - The gross profit from toxic decoction pieces was 34.298 million RMB (29.7%) in 2022, 46.158 million RMB (24.0%) in 2023, and is expected to be 32.862 million RMB (19.1%) in 2024. For ordinary decoction pieces, gross profit was 130.343 million RMB (19.6%) in 2022, 165.860 million RMB (17.4%) in 2023, and is projected to be 180.211 million RMB (16.7%) in 2024 [5]. Profit Summary - The net profit for the years 2022, 2023, and 2024 is expected to be 77.395 million RMB, 103.974 million RMB, and 89.112 million RMB respectively, with net profit margins of 9.9%, 9.1%, and 7.1% [6]. Company Background and IPO Attempts - Xin He Hua was established in 2001 and has made multiple attempts to go public, including an IPO application in 2010 that was withdrawn due to allegations of financial misconduct. The company re-applied for an IPO in 2020 but withdrew the application again in 2021 [7]. - In October 2023, Xin He Hua registered for counseling with the Sichuan Securities Regulatory Bureau, with plans to terminate the counseling by April 2024. The funds raised are intended for expanding production capacity, upgrading digital production systems, marketing activities, establishing overseas sales channels in Vietnam and Malaysia, strategic investments, and general corporate purposes [8].